Overview

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Study objective is to determine whether Pioglitazone (PGZ) can improve clinical outcomes in hyperglycemic acute ischemic stroke (IS). The rationale for the proposed research is to develop an acute intervention that can improve neurological recovery and decrease mortality and morbidity in high-risk diabetic stroke patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborator:
National Center for Advancing Translational Science (NCATS)
Treatments:
Pioglitazone